Anzeige
Mehr »
Mittwoch, 06.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C5SS | ISIN: BMG889121031 | Ticker-Symbol: 0RP
Tradegate
05.08.25 | 08:27
2,080 Euro
-0,95 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES LTD Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,9302,04005.08.

Aktuelle News zur TIZIANA LIFE SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.07.Tiziana Life Sciences: Lucid Capital Markets startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial14
22.07.Tiziana Life Sciences stock initiated with Buy rating at Lucid Capital Markets1
21.07.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient601NEW YORK, July 21, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
21.07.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer3
13.06.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center369NEW YORK, June 13, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
13.06.Tiziana shares rise on presentation date for foralumab data4
TIZIANA LIFE SCIENCES Aktie jetzt für 0€ handeln
13.06.Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Bio International Convention313NEW YORK, June 13, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
13.06.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
23.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease409NEW YORK, May 23, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
23.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer2
15.05.Tiziana Life Sciences Ltd.: Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease444NEW YORK, May 15, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
15.05.Tiziana Life Sciences Ltd - 6-K, Report of foreign issuer1
12.05.Tiziana Chairman Gabriele Cerrone Boosts Stake To 37% With Share Purchase3
12.05.Tiziana Life Sciences reports purchase of shares by chairman3
12.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Shares by Chairman289NEW YORK, May 12, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
09.05.Tiziana posts favorable PET scan data for lead asset in Alzheimer's1
09.05.Tiziana reports promising Alzheimer's treatment results1
09.05.Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab354NEW YORK, May 09, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...
► Artikel lesen
08.05.Tiziana Life Sciences' intranasal MS candidate shows promise in open-label study1
06.05.Tiziana Life Sciences Ltd - 20-F, Annual and transition report of foreign private issuers1
Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1